ulcerative colitis
MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance
January 27, 2026FDA, Gastrointestinal tract, MRM Health, ulcerative colitis
Microbial Resource Management (MRM) Health has announced that its lead programme, MH002, has received Investigational New Drug (IND) clearance from …
Polpharma Biologics and Fresenius Kabi partner to develop treatment for ulcerative colitis and Crohn’s disease
August 5, 2025Mergers and Acquisitions Corporate, Crohn’s disease, Fresenius Kabi, Gastrointestinal tract, Polpharma Biologics, ulcerative colitis
Polpharma Biologics has signed a global licensing agreement with Fresenius Kabi for the commercialisation of PB016, a proposed biosimilar to …
Ferring demonstrates effectiveness of a treat-to-target approach in mild-to-moderate ulcerative colitis in first major study
October 3, 2024Research and Development Ferring Pharmaceuticals, Gastrointestinal tract, ulcerative colitis
1 October 2024 – Saint-Prex, Switzerland – Ferring Pharmaceuticals today announces results from the OPTIMISE study showing the first real-world …
The National Institute for Health and Care Excellence announce technology appraisal guidance recommending risankizumab for adult patients with moderate to severe ulcerative colitis
August 29, 2024Research and Development AbbVie, Crohns, Gastrointestinal tract, Immunology, NICE, approval, ulcerative colitis
The National Institute for Health and Care Excellence (NICE) have recommended adult patients in England or Wales with moderately or …
AbbVie gains positive CHMP opinion for Skyrizi for treatment of UC
May 31, 2024Medical Communications AbbVie, EMA, Gastrointestinal tract, Skyrizi, ulcerative colitis
AbbVie has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted a …
J&J’s Tremfya meets primary and secondary endpoints in UC maintenance study
May 21, 2024Medical Communications Gastrointestinal tract, J&J, Johnson & Johnson, clinical trial, ulcerative colitis
Johnson & Johnson (J&J) has announced the first data from its phase 3 QUASAR maintenance study which assessed Tremfya (guselkumab) …
Pfizer’s Velsipity approved by EC for ulcerative colitis treatment
February 20, 2024Medical Communications European Commission, Gastrointestinal tract, Pfizer, Velsipity, ulcerative colitis
Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Velsipity (etrasimod) in the European Union (EU). …
Landos Biophama shares results from phase 1b trial for ulcerative colitis treatment
November 23, 2023Medical Communications Gastrointestinal tract, Landos Biopharma, clinical trial, ulcerative colitis
Landos Biopharma has announced that it has shared safety, tolerability, pharmacokinetics and clinical efficacy results for the NX-13 phase 1b …
Eli Lilly’s Omvoh receives FDA approval for ulcerative colitis treatment
October 27, 2023Medical Communications Eli Lilly, FDA, Gastrointestinal tract, Omvoh, ulcerative colitis
Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Omvoh (mirikizumab-mrkz) infusion (300mg/15mL)/injection (100mg/mL) for …
Sanofi and Teva partner for development of inflammatory bowel disease treatment
October 4, 2023Medical Communications Crohn’s disease, Gastrointestinal tract, Sanofi, Teva, bowel disease, ulcerative colitis
Sanofi and Teva Pharmaceuticals have announced that they will collaborate for the co-development and co-commercialisation of TEV’574, a treatment for …
OSE Immunotherapies’ UC drug gets DSMB positive recommendation
July 6, 2023Research and Development EMA, Gastrointestinal tract, OSE Immunotherapeutics, ulcerative colitis
French biotech company OSE Immunotherapeutics has announced that its Ulcerative Colitis (UC) trial’s Independent Drug Safety Monitoring Board (DSMB) has provided …
Amsterdam UMC’s new drug doubles remission rates in patients with ulcerative colitis
July 4, 2023Research and Development Amsterdam UMC, Gastrointestinal tract, mirikizumab, ulcerative colitis
A new drug, being investigated by Amsterdam UMC along with colleagues at various universities, has been shown to be effective …
Lilly’s ulcerative colitis treatment meets all key endpoints in Phase III trial
March 17, 2021Research and Development Eli Lilly, Phase III trial, lilly, mirikizumab, ulcerative colitis
Eli Lilly’s mirikizumab treatment for ulcerative colitis (UC) patients has met the primary endpoints and all key secondary endpoints in …
Roche’s entrolizumab disappoints at Phase 3 in moderately to severely active ulcerative colitis
August 11, 2020Manufacturing and Production, Research and Development Roche, etrolizumab, trial failure, ulcerative colitis
Roche has voiced its disappointment after its investigational therapy etrolizumab showed “mixed results” as a treatment for moderately to severely …
Takeda’s subcutaneous Entyvio approved in Europe for maintenance of moderate to severe Crohn’s and ulcerative colitis
May 11, 2020Sales and Marketing Crohn’s disease, Entyvio, Takeda, crohn's disease, ulcerative colitis
The European Commission has awarded marketing approval to Takeda’s subcutaneous formulation of its gut-selective biologic therapy Entyvio (vedolizumab) as a …
